Antitumor activity of pyridocarbazole and benzopyridoindole derivatives that inhibit protein kinase CK2

Cancer Research

Volumn 70, Issue 23, 2010, Pages 9865-9874

  Prudent, Renaud ^a,b,c   Moucadel, Virginie ^a,b,c   Nguyen, Chi Hung ^d   Barette, Caroline ^e   Schmidt, Frédéric ^d,e   Florent, Jean Claude ^d,e   Lafanechère, Laurence ^e   Sautel, Céline F ^a,b,c   Duchemin Pelletier, Eve ^a,b,c   Spreux, Elodie ^a,b,c   Filhol, Odile ^a,b,c   Reiser, Jean Baptiste ^f   Cochet, Claude ^a,b,c  

^a INSERM   (France)

^b CEA GRENOBLE   (France)

^c UNIV GRENOBLE ALPES   (France)

^d INSTITUT CURIE   (France)

^e CNRS   (France)

^f INSTITUT DE BIOLOGIE STRUCTURALE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BENZOPYRIDOINDOLE DERIVATIVE; CASEIN KINASE II; ELLIPTICINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIDOCARBAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE ARREST; DRUG IDENTIFICATION; DRUG INHIBITION; DRUG POTENCY; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; FEMALE; GLIOBLASTOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MYOSARCOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN PURIFICATION; TUMOR XENOGRAFT; UTERINE CERVIX CARCINOMA; X RAY CRYSTALLOGRAPHY;

EID: 78649929740     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-0917     Document Type: Article

References (44)

1. Ahmed K, Gerber DA, Cochet C. Joining the cell survival squad: an emerging role for protein kinase CK2. Trends Cell Biol 2002;12:226-30.
2. Litchfield DW. Protein kinase CK2: structure, regulation and role in cellular decisions of life and death. Biochem J 2003;369:1-15.
3. Tawfic S, Yu S, Wang H, Faust R, Davis A, Ahmed K. Protein kinase CK2 signal in neoplasia. Histol Histopathol 2001;16:573-82.
4. Laramas M, Pasquier D, Filhol O, Ringeisen F, Descotes JL, Cochet C. Nuclear localization of protein kinase CK2 catalytic subunit (CK2alpha) is associated with poor prognostic factors in human prostate cancer. Eur J Cancer 2007;43:928-34.
5. Kim JS, Eom JI, Cheong JW, Choi AJ, Lee JK, Yang WI, et al. Protein kinase CK2alpha as an unfavorable prognostic marker and novel therapeutic target in acute myeloid leukemia. Clin Cancer Res 2007;13:1019-28.
6. Pagano MA, Cesaro L, Meggio F, Pinna LA. Protein kinase CK2: a newcomer in the 'druggable kinome'. Biochem Soc Trans 2006;34:1303-6.
7. Duncan JS, Gyenis L, Lenehan J, Bretner M, Graves LM, Haystead TA, et al. An unbiased evaluation of CK2 inhibitors by chemo-proteomics: characterization of inhibitor effects on CK2 and identification of novel inhibitor targets. Mol Cell Proteom 2008;7:1077-88.
8. De Moliner E BN, Johnson LN. Alternative binding modes of an inhibitor to two different kinases. Eur J Biochem 2003;270:3174-81.
9. Meggio F, Pagano MA, Moro S, Zagotto G, Ruzzene M, Sarno S, et al. Inhibition of protein kinase CK2 by condensed polyphenolic derivatives. An in vitro and in vivo study. Biochemistry 2004;43:12931-6.
10. Loizou JI, El-Khamisy SF, Zlatanou A, Moore DJ, Chan DW, Qin J, et al. The protein kinase CK2 facilitates repair of chromosomal DNA single-strand breaks. Cell 2004;117:17-28.
11. Lopez-Ramos M, Prudent R, Moucadel V, Sautel CF, Barette C, Lafanechère L, et al. New potent dual inhibitors of CK2 and Pim kinases: discovery and structural insights. FASEB J. 2010;24:3171-85.
12. Auclair C. Multimodal action of antitumor agents on DNA: the ellipticine series. Arch Biochem Biophys 1987;259:1-14.
13. Kohn KW, Waring MJ, Glaubiger D, Friedman CA. Intercalative binding of ellipticine to DNA. Cancer Res 1975;35:71-6.
14. Tewey KM, Chen GL, Nelson EM, Liu LF. Intercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II. J Biol Chem 1984;259:9182-7.
15. Fosse P, Rene B, Le Bret M, Paoletti C, Saucier JM. Sequence requirements for mammalian topoisomerase II mediated DNA cleavage stimulated by an ellipticine derivative. Nucleic Acids Res 1991;19:2861-8.
16. Stiborova M, Breuer A, Aimova D, Stiborova-Rupertova M, Wiessler M, Frei E. DNA adduct formation by the anticancer drug ellipticine in rats determined by 32P postlabeling. Int J Cancer 2003;107: 885-90.
17. Peng Y, Li C, Chen L, Sebti S, Chen J. Rescue of mutant p53 transcription function by ellipticine. Oncogene 2003;22:4478-87.
18. Sugikawa E, Hosoi T, Yazaki N, Gamanuma M, Nakanishi N, Ohashi M. Mutant p53 mediated induction of cell cycle arrest and apoptosis at G1 phase by 9-hydroxyellipticine. Anticancer Res 1999;19: 3099-108.
19. Kuo YC, Kuo PL, Hsu YL, Cho CY, Lin CC. Ellipticine induces apoptosis through p53-dependent pathway in human hepatocellular carcinoma HepG2 cells. Life Sci 2006;78:2550-7.
20. Ohashi M, Sugikawa E, Nakanishi N. Inhibition of p53 protein phosphorylation by 9-hydroxyellipticine: a possible anticancer mechanism. Jpn J Cancer Res 1995;86:819-27.
21. Vendome J, Letard S, Martin F, Svinarchuk F, Dubreuil P, Auclair C, et al. Molecular modeling of wild-type and D816V c-Kit inhibition based on ATP-competitive binding of ellipticine derivatives to tyrosine kinases. J Med Chem 2005;48:6194-201.
22. Prudent R, Moucadel V, Lopez-Ramos M, Aci S, Laudet B, Mouawad L, et al. Expanding the chemical diversity of CK2 inhibitors. Mol Cell Biochem 2008;316:71-85.
23. Filhol O, Cochet C, Delagoutte T, Chambaz EM. Polyamine binding activity of casein kinase II. Biochem Biophys Res Commun 1991;180:945-52.
24. Ermakova I, Boldyreff B, Issinger OG, Niefind K. Crystal structure of a C-terminal deletion mutant of human protein kinase CK2 catalytic subunit. J Mol Biol 2003;330:925-34.
25. Kabsch W. Automatic processing of rotation diffraction data from crystals of initially unknown symmetry and cell constants. J Appl Cryst 1993;26:795-800.
26. Navaza J. AMoRe: an automated package for molecular replacement. Acta Cryst 1994;A50:157-63.
27. Collaborative Computational Project, Number 4. The CCP4 suite: programs for protein crystallography. Acta Crystallogr D Biol Crystallogr 1994;50:760-3.
28. Emsley P, Cowtan K. Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr 2004;60:2126-32.
29. Murshudov GN, Vagin AA, Dodson EJ. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr D Biol Crystallogr 1997;53:240-55.
30. Prudent R, Lopez-Ramos M, Moucadel V, Barette C, Grierson D, Mouawad L, et al. Salicylaldehyde derivatives as new protein kinase CK2 inhibitors. Biochim Biophys Acta 2008;1780:1412-20.
31. Nguyen CH, Lhoste JM, Lavelle F, Bissery MC, Bisagni E. Synthesis and antitumor activity of 1-[[(dialkylamino)alkyl]amino]-4-methyl-5H-pyrido[4,3-b] benzo[e]- and -benzo[g])indoles. A new class of antineoplastic agents. J Med Chem 1990;33:1519-28.
32. Vinogradov S, Roig V, Sergueeva Z, Nguyen CH, Arimondo P, Thuong NT, et al. Synthesis and binding properties of oligo-2′- deoxyribonucleotides conjugated with triple-helix-specific intercalators: benzo[e] and benzo[g] pyridoindoles. Bioconjug Chem 2003;14:120-35.
33. Riou JF, Fosse P, Nguyen CH, Larsen AK, Bissery MC, Grondard L, et al. Intoplicine (RP 60475) and its derivatives, a new class of antitumor agents inhibiting both topoisomerase I and II activities. Cancer Res 1993;53:5987-93.
34. Prudent R, Lopez-Ramos M, Moucadel V, Barette C, Grierson D, Mouawad L, et al. Salicylaldehyde derivatives as new protein kinase CK2 inhibitors. Biochim Biophys Acta 2008;1780:1412-20.
35. Kuo PL, Hsu YL, Chang CH, Lin CC. The mechanism of ellipticine-induced apoptosis and cell cycle arrest in human breast MCF-7 cancer cells. Cancer Lett 2005;223:293-301.
36. Yde CW, Ermakova I, Issinger OG, Niefind K. Inclining the purine base binding plane in protein kinase CK2 by exchanging the flanking side-chains generates a preference for ATP as a cosubstrate. J Mol Biol 2005;347:399-414.
37. Prudent R, Cochet C. New protein kinase CK2 inhibitors: jumping out of the catalytic box. Chem Biol 2009;16:112-20.
38. Prudent R, Moucadel V, Laudet B, Barette C, Lafanechère L, Hasenknopf B, et al. Identification ofpolyoxometalates as nanomolar noncompetitive inhibitors of protein kinase CK2. Chem Biol 2008;15: 683-92.
39. Meggio F, Pinna LA. One-thousand-and-one substrates of protein kinase CK2?FASEB J 2003;17:349-68.
40. Ruzzene M, Pinna LA. Addiction to protein kinase CK2: A common denominator of diverse cancer cells?Biochim Biophys Acta 2009;1804:499-504.
41. Cibull TL, Jones TD, Li L, Eble JN, Ann Baldridge L, Malott SR, et al. Overexpression of Pim-1 during progression of prostatic adenocarcinoma. J Clin Pathol 2006;59:285-8.
42. Sanjo H, Kawai T, Akira S. DRAKs, novel serine/threonine kinases related to death-associated protein kinase that trigger apoptosis. J Biol Chem 1998;273:29066-71.
43. Frantz S. Drug discovery: playing dirty. Nature 2005;437:942-3.
44. Sawyers CL. Opportunities and challenges in the development of kinase inhibitor therapy for cancer. Genes Dev 2003;17:2998-3010.